cytarabine has been researched along with eriodictyol in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, M; He, Y; Huang, H; Ji, L; Li, Y; Wu, M | 1 |
1 other study(ies) available for cytarabine and eriodictyol
| Article | Year |
|---|---|
Eriodictyol suppresses the malignant progression of colorectal cancer by downregulating tissue specific transplantation antigen P35B (TSTA3) expression to restrain fucosylation.
Topics: Carbohydrate Epimerases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Flavanones; Glycosylation; Guanosine Diphosphate Fucose; Humans; Ketone Oxidoreductases | 2022 |